“…However, poor cellular uptake of PNA has been a major impediment in the development of this class of compounds as therapeutic agents. Various approaches have been adopted for the ef cient biodelivery of PNA into cells, including conjugation to lipophilic moieties (Ljungstrom et al, 1999;Muratovska et al, 2001), cell-speci c receptor ligands (Basu and Wickstrom, 1997;Boffa et al, 2000;Zhang et al, 2001), carrier peptides (Cutrona et al, 2000), neamine (Riguet et al, 2004), and guanidine-based PNA (Zhou et al, 2003) electrostatically bound with the polymeric core shell microsphere (Chiarantini et al, 2005) or loaded into the autologous red blood cells (Chiarantini et al, 1995;Turrini et al, 1991). We have demonstrated that polyamide nucleic acids complementary to the transactivation response (TAR) element of HIV-1 LTR inhibit HIV-1 production when transfected in HIV-1 infected cells.…”